Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study

被引：0
|
作者：
Yao Zhang
Hexiang Yin
Dingding Zhang
Yan Xu
Bin Peng
Liying Cui
机构：
[1] Center of Multiple Sclerosis and Related Disorders,Department of Neurology
[2] Peking Union Medical College Hospital,Medical Research Center
[3] Peking Union Medical College Hospital,Neurosciences Center
[4] Peking Union Medical College & Chinese Academy of Medical Sciences,undefined
[5] Peking Union Medical College Hospital,undefined
[6] Peking Union Medical College & Chinese Academy of Medical Sciences,undefined
[7] Chinese Academy of Medical Sciences,undefined
来源：
Journal of Neurology | 2022年 / 269卷
关键词：
Multiple sclerosis; Teriflunomide; Real-world; No evidence of disease activity (NEDA); Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4808 / 4816
页数：8
相关论文
共 50 条
  • [31] The Danish experience of teriflunomide treatment in relapsing remitting multiple sclerosis
    Magyari, M.
    Buron, M.
    Illes, Z.
    Sellebjerg, F.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 472 - 472
  • [32] Patient-reported outcomes to assess quality of life in teriflunomide-treated patients with relapsing-remitting multiple sclerosis: Results of Teri-REAL - a real-world study from Hungary
    Vecsei, L.
    Bencsik, K.
    Dobos, E.
    Jobbagy, Z.
    Birkas, A. Jori
    Kovacs, K.
    Satori, M.
    Bartok, G.
    Losonczi, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 708 - 709
  • [33] High persistence rate and sustained efficacy of teriflunomide in relapsing-remitting multiple sclerosis in real-world practice: a 3-year retrospective, multicenter study
    Villafani, J.
    Pena, J.
    Gonzalez-Quintanilla, V.
    Oliva, P.
    Suarez, R.
    Solar, D. M.
    Fernandez-Uria, D.
    Perez, D.
    Lara, L.
    Hernandez, L.
    Ares, A.
    Rodriguez, E.
    Oterino, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 704 - 705
  • [34] Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study
    Bencsik, Krisztina
    Dobos, Eniko
    Jobbagy, Zita
    Birkas, Adrienne Jori
    Kovacs, Krisztina
    Satori, Maria
    Lencses, Gyula
    Bartok, Gabor
    Losonczi, Erika
    Vecsei, Laszlo
    PHARMACEUTICALS, 2022, 15 (05)
  • [35] Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
    Papadopoulou, Athina
    Kappos, Ludwig
    Sprenger, Till
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 749 - 759
  • [36] The cost of teriflunomide in the treatment of relapsing- remitting multiple sclerosis
    Millar, J. Alasdair
    NEW ZEALAND MEDICAL JOURNAL, 2019, 132 (1490) : 36 - 41
  • [37] Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina
    Patrucco, Liliana
    Cristiano, Edgardo
    Sanchez, Francisco
    Miguez, Jimena
    Rojas, Juan Ignacio
    CLINICAL NEUROPHARMACOLOGY, 2019, 42 (05) : 163 - 166
  • [38] Real-world assessment of quality of life through patient-reported outcomes in relapsing-remitting multiple sclerosis patients treated with teriflunomide for two years. Outcomes of the AURELIO study in Greece
    Dardiotis, E.
    Perpati, G.
    Nikolaidis, I.
    Tzanetakos, D.
    Deretzi, G.
    Kilidireas, C.
    Mitsikostas, D. -D.
    Hadjigeorgiou, G.
    Grigoriadis, N.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 716 - 717
  • [39] Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in Kuwait
    AL-Hashel, Jasem
    Ahmed, Samar F.
    Behbehani, Raed
    Alroughani, Raed
    CNS DRUGS, 2014, 28 (09) : 817 - 824
  • [40] Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in Kuwait
    Jasem AL-Hashel
    Samar F. Ahmed
    Raed Behbehani
    Raed Alroughani
    CNS Drugs, 2014, 28 : 817 - 824
12345